We are live on ! Find out more
ALT icon

Altimmune
ALT

173 hedge funds and large institutions have $214M invested in Altimmune in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 82 increasing their positions, 34 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

254% more capital inflows, than outflows

Capital inflows: $143M | Capital outflows: $40.5M

225% more call options, than puts

Call options by funds: $10.4M | Put options by funds: $3.21M

141% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 34

0.55% more ownership

Funds ownership: 52.77% → 53.32% (+0.55%)

5% less funds holding

Funds holding: 182 → 173 (-9)

14% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 35

Holders
173
Holders Change
-9
Holders Change %
-4.95%
% of All Funds
2.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
82
Reduced
34
Closed
35
Calls
$10.4M
Puts
$3.21M
Net Calls
+$7.22M
Net Calls Change
+$9.8M

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$13.1M
2
BlackRock
BlackRock
New York
+$13.1M
3
Millennium Management
Millennium Management
New York
+$13M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$11.2M
5
State Street
State Street
Massachusetts
+$8.6M

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$7.57M
2
Tang Capital Management
Tang Capital Management
California
-$6.22M
3
KCM
Knoll Capital Management
Florida
-$4.08M
4
Citadel Advisors
Citadel Advisors
Florida
-$3.77M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.62M

ALT Hedge Fund Activity: Q1 2026 in Review

173 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2026, worth a combined $214M — up 7.4% from $199M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ALT and 30 opened new positions — a net loss of 5 holders — while 34 trimmed existing stakes and 82 added.

The largest buyer was Marshall Wace, adding an estimated $13.1M. The largest seller was Jane Street, exiting entirely with an estimated $7.57M sold.

  • 173 institutional investors held Altimmune (ALT) as of Q1 2026, down from 182 in Q4 2025.
  • Funds reported $214M of Altimmune stock for Q1 2026, up 7.4% quarter-over-quarter.
  • 30 funds opened new Altimmune positions in Q1 2026 and 35 closed out, a net change of -5 holders.
  • The largest Altimmune buyer in Q1 2026 was Marshall Wace, an estimated $13.1M added.
  • The largest Altimmune seller in Q1 2026 was Jane Street, an estimated $7.57M sold.

Based on aggregated 13F filings for Q1 2026.